- Boston Scientific (BSX) has reported favorable results in almost a dozen studies that tested the company's cardiac resynchronization therapy (CRT) defibrillators, platinum chromium stent platforms, and transcatheter aortic valve replacement.
- Boston Scientific presented the data at the American College of Cardiology's Annual Scientific Session.
- In a long-term study of patients with mild heart failure, there was a 41% relative reduction in the risk of death in those who received a Boston Scientific defibrillator with CRT compared with patients who received just a defibrillator. (PR)
From other sites
at CNBC.com (Jan 5, 2015)
at CNBC.com (Nov 19, 2014)
at CNBC.com (Nov 14, 2014)
at CNBC.com (Nov 5, 2014)
at CNBC.com (Nov 3, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs